Revance and Teoxane announced FDA approval for RHA Dynamic Volume from the Teoxane RHA collection for cheek augmentation and correction of age-related contour changes in the midface for adults aged 22 and older. The publication notes that the product was previously known as RHA 4 Mepi, and the official launch under the new name RHA Dynamic Volume is scheduled for the first quarter of 2026.
The companies emphasize that the product is designed for dynamic contour modeling and structural support. According to their description, RHA Dynamic Volume is meant to provide a natural appearance both at rest and in motion, maintaining structural integrity and adapting to facial expressions. It is specifically highlighted that the filler operates on Preserved Network Technology—a gentle, homogeneous cross-linking process without heat, which helps preserve the natural structure of hyaluronic acid.
"We are extremely proud of the approval of RHA Dynamic Volume for the midface. This news marks the second major step forward for the Teoxane RHA collection in recent months following the line's development through the introduction of the local anesthetic Mepivacaine at the end of August. The new indication for the midface allows us to meet more patient needs than ever before."
Nadim Moiz, CEO of Revance.
Revance also stated that they continue to work on innovations and aim to offer a variety of treatment options for a wide range of aesthetic patient requests.
What exactly did the FDA approve for RHA Dynamic Volume?
The approval covers two application areas within a single regulatory decision: cheek augmentation and correction of age-related contour changes in the midface. This means the product received official approval specifically for working with volume and contours of the midface, rather than just a general positioning as a hyaluronic acid-based filler.
In the context of aesthetic medicine practice, this is significant because the midface remains one of the key areas where age-related changes affect projection, tissue support, and the overall perception of the face. Therefore, the new approval is presented as a separate step in the development of the Teoxane RHA collection.
On what clinical data is the decision based?
The FDA approval, as noted in the publication, is supported by positive results from a 52-week Phase III clinical trial program. In it, the efficacy and safety of RHA Dynamic Volume were evaluated in a prospective, randomized, multicenter, double-blind study compared to Juvéderm Voluma XC in patients with moderate to severe volume deficiency in the midface.
According to the companies, RHA Dynamic Volume demonstrated comparable efficacy to Voluma. At the same time, patients receiving RHA Dynamic Volume required fewer treatment sessions and fewer corrective touch-up procedures to achieve similar results. Patients also reported improvements in attractiveness, a more youthful appearance, smoothness, contours, and cheek symmetry.
It is specifically noted in the material that over 94% of participants reported a natural look and feel of the result at rest and during movement for up to one year after the procedure. Patients also did not report any feeling of facial stiffness, which, according to the companies, confirms the filler’s adaptability to dynamic facial expressions.
During the clinical program, 75% of participants received treatment simultaneously in both superficial and deep fat pads to achieve balanced volume restoration. The publication emphasizes that RHA Dynamic Volume demonstrated a favorable safety profile: no late or serious adverse events related to the treatment were reported, nor were there any events recognized as granulomas or delayed inflammatory reactions.
What does this mean for midface correction?
Teoxane and Revance present this approval as an important step for modern midface contouring, where the physician works not only with a single point of deficit but with comprehensive restoration of volume, contours, and proportions. The main focus is on combining structural support, natural integration into tissues, and preserving lively facial expressions.
In this context, RHA Dynamic Volume is described as a filler that combines high projection capability with dynamic adaptability. The publication emphasizes that such a profile can be particularly important for the midface, where the result should look natural not only in photos but also in motion.
How is the Teoxane MLT Multilayering Technique described in the release?
The material pays special attention to the Teoxane MLT Multilayering Technique—an individualized injection approach for restoring midface volume using a single adaptive gel, RHA Dynamic Volume. Teoxane explains that the technique involves strategic injection of the product into subcutaneous and supraperiosteal layers to restore volume, redefine contours, and harmonize facial proportions according to the anatomy and aging pattern of the specific patient.
The company also emphasizes that this approach is based on anatomical precision and the proprietary ATP logic—Anatomy, Assessment & Ageing, Technique, Product. According to the release description, the technique emphasizes safety and precision by identifying and avoiding high-risk vascular zones, resulting in delicate natural rejuvenation without excessive correction.
"This study marks the entry into the U.S. market of a midface contour correction approach that has been supported by post-marketing surveillance data in Europe for over ten years. Thanks to the versatility of RHA Dynamic Volume and the Teoxane MLT Multilayering Technique, physicians can now address midface volume deficiency by impacting multiple tissue levels—both deep and superficial fat pads."
Sandra Shennoufi, Chief Scientific Officer at Teoxane.
What do researchers say about the new approval?
The publication also includes an assessment by Dr. Steven Dayan, a double board-certified facial plastic surgeon and Clinical Assistant Professor at the University of Illinois. He calls the approval of RHA Dynamic Volume for the midface an important step for the entire industry and emphasizes the significance of the results obtained during the study.
"The approval of RHA Dynamic Volume for the midface is an exciting step forward for the entire industry. The results we saw during the study were truly impressive, and I am thrilled to have the opportunity to offer my patients an individualized treatment option."
Dr. Steven Dayan, facial plastic surgeon and Clinical Assistant Professor at the University of Illinois.
Brief Overview of Revance and Teoxane
Revance is described in the publication as a global company in the field of aesthetics and skincare, developing innovative solutions for various stages of life. Its portfolio includes DAXXIFY, the Teoxane RHA collection, and SkinPen, as well as consumer skincare brands such as PanOxyl, Blue Lizard, StriVectin, and BIOJUVE.
It is specifically noted that the RHA technology is a proprietary development of Teoxane and is manufactured in Switzerland by Teoxane SA, while Revance serves as the independent distributor of the Teoxane RHA collection in the U.S. Therefore, the news of FDA approval is presented as a joint achievement of Revance and Teoxane.
